Peer-reviewed veterinary case report
VISTA immune protein in canine mammary tumors and treatment potential
By Yamac, Muhammed Ali et al.·Published in Research in veterinary science·2025·Burdur Mehmet Akif Ersoy University·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immunohistochemical profiling of VISTA expression in canine mammary tumors: A pilot study for immunotherapeutic targeting.
- Species:
- dog
Plain-English summary
A study looked at the presence of a protein called VISTA in mammary tumors from 26 dogs diagnosed with cancer. Researchers found that higher tumor grades had more intense VISTA expression in the cancer cells, suggesting that VISTA could be important for understanding the disease and developing new treatments. While the study didn't find significant differences in VISTA levels among different tumor types, the findings indicate that VISTA might be a useful marker for future immunotherapy options in dogs with mammary cancer.
People also search for: dog mammary tumor treatment · VISTA protein in dog cancer · canine breast cancer prognosis
Abstract
VISTA (V-domain Ig-containing suppressor of T cell activation) is an immune checkpoint protein that regulates the activity of T cells and is involved in immune tolerance. Although its role has been elucidated in human oncology, its significance in canine mammary tumors (CMTs) is unclear. This research was focused on investigating VISTA expression in CMTs and its correlation with histologic grade and molecular subtype. Archived formalin-fixed, paraffin-embedded mammary gland tumors taken from 26 canine patients diagnosed with malignant tumors were studied. Histopathologic classification and grading were performed using hematoxylin and eosin-stained sections. Immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PR), HER2, and VISTA was done, and molecular subtypes were defined as based on ER, PR, and HER2 status. VISTA immunoreactivity was semiquantitatively evaluated in tumor cells and in inflammatory cells. VISTA expression in neoplastic cells and in cells of the inflammatory infiltrate was found. Increased tumor grade was found to have significantly increased VISTA staining intensity and overall score in tumor cells. Inflammatory cell staining differed according to grade, yet this difference was not significant. No significant difference in VISTA expression was detected in molecular subtypes. This is the initial research to shed light on VISTA expression in CMTs. Its identification within tumor cells and within cells of the infiltrate, and its correlation with tumor grade, places its importance as an immunotherapeutic and prognostic marker in mammary cancer in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40651355/